Federal Circuit overturns District Court decision on Angiomax patents; Grants The Medicines Company’s request for rehearing of appeal

13 Nov 2015

The Medicines Company’s petition for en banc review of the U.S. Court of Appeals for the Federal Circuit’s decision in The Medicines Company v. Hospira, Inc. was granted. This vacates the Court’s earlier decision invalidating the Orange Book patents covering Angiomax® that expire in 2028 (pediatric exclusivity expiring in 2029). The Court requested briefing concerning the commercial on-sale bar issue. It has requested the views of the United States Department of Justice, and will also allow other amicus curiae to submit their views.

Clive Meanwell, MD, PhD, Chief Executive Officer, The Medicines Company, said “We are extremely pleased that the invalidity decision has been vacated, and that the entire Appeals Court will now review the issue anew. We continue to believe that our patents are valid and infringed by the ANDA filers, and are now considering all of our options with respect to Hospira, Mylan, and other generics.”

About The Medicines Company

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: serious infectious disease care, acute cardiovascular care and surgery and perioperative care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

Forward-Looking Statements

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" "expects" and “potential” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the Company can protect its intellectual property and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 9, 2015, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.


The Medicines Company
Bob Laverty, +1 973-290-6162
Mobile +1 609-558-5570
Vice President, Communications
Investor Relations:
Krishna Gorti, MD, +1 973-290-6122
Vice President, Investor Relations

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information